Supplementary Table 1 and Figure S1- S8 from Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor
Remi Adelaiye‐Ogala(Roswell Park Comprehensive Cancer Center), David James VanderWeele(Northwestern University), Adlai R. Grayson(Center for Cancer Research), Wardah Bajwa(Center for Cancer Research), Brian J. Capaldo(University of Virginia), Jose Antonio Rodriguez-Nieves(University of Massachusetts Boston), Supreet Agarwal(University of Iowa), Kathleen Kelly(The Ohio State University), Aian Neil Alilin(National Cancer Institute), Yen Thi Minh Nguyen(Center for Cancer Research), Michael L. Beshiri(National Cancer Institute), Berkley E. Gryder(University School), Keith H. Jansson(National Cancer Institute)
Cited by 0
Related Papers
Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor
|Cell|1983|2.3k
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
|Nature Communications|2016|435
PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
|Cancer Discovery|2017|336
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
|Journal for ImmunoTherapy of Cancer|2018|314